Effect of amlodipine on systolic blood pressure

Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)

“…Furthermore, the efficacy and safety profile of single-pill amlodipine/atorvastatin therapy were comparable with that observed in previous placebo-controlled studies of co-administered amlodipine and atorvastatin or the individual drugs. 17,18,[23][24][25]27,28,33,50 Overall, a higher incidence of AEs, and in particular peripheral oedema, was reported for Latin America than for the other regions in the study. We are unable to determine from the study data whether this is related to ethnic differences between the study populations, or if this is a result of regional differences in diagnosis or AE reporting.…”

“…16 Both amlodipine and atorvastatin have been shown to be efficacious and safe for lowering BP and lipid levels, respectively, as well as reducing the incidence of CV events. [17][18][19][20][21][22] Furthermore, both coadministered amlodipine and atorvastatin, or singlepill amlodipine/atorvastatin, are an effective and safe means of helping patients attain recommended BP and lipid targets. [23][24][25][26][27][28] Limited data are currently available concerning the treatment patterns for patients with hypertension and dyslipidaemia in countries across the Middle East, Asia-Pacific, Africa and Latin America; to date, no large-scale clinical trial has been undertaken to study the treatment of more than one CV risk factor in hypertensive patients across these regions.…”

Estimating the proportion of young adults on antihypertensive treatment that have been correctly diagnosed

“…There is some evidence that calcium channel blockers may be more effective and angiotensin converting enzyme (ACE) inhibitors less effective in older subjects, but there is little conclusive evidence for those under 35. [5][6][7] We repeated the analysis with the assumption that the effect of treatment in young adults was 50% greater than estimated from meta-analysis. 3 Does the assumption that the effects of treatment are the same on all individuals affect the results?…”

Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: A potential treatment of salt-dependent hypertension

“…Treatment of hypertension can effectively reduce cardiovascular morbidity and mortality, even in the case of isolated systolic hypertension or mild to moderate forms of hypertension (1,2). Historically, the first antihypertensive drugs used were sympathicolytic agents and diuretics.…”

“…However, they cause a number of secondary side effects and are thus not the first choice of drugs. Blockers of the renin-angiotensin system (RAS), either angiotensin I-converting enzyme (ACE) inhibitors or angiotensin II (AngII) receptor type 1 (AT 1 ) antagonists, have proved to be efficient and safe (3). ACE inhibitors cause cough and more rarely angioedema (4)(5)(6), and renal function may deteriorate with both ACE inhibitors and AT 1 receptor antagonists in cases of underlying renal artery stenosis (7)(8)(9).…”